Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps.

To evaluate within-patient symptom improvement in the dupilumab SINUS-24/-52 studies in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT02912468/NCT02898454). Patients received dupilumab 300 mg or placebo every 2 weeks for 24 (SINUS-24) or 52 weeks (SINUS-52) on background intranasal corticosteroids. Patients daily reported symptoms of nasal congestion (NC), loss of smell (LoS) and rhinorrhoea on a scale of 0-3 (0 - no symptoms, 1 - mild, 2 - moderate, 3 - severe symptoms). The proportions of patients with moderate-to-severe symptoms (score ≥ 2) at baseline who improved to no-to-mild symptoms (score ≤ 1) were determined at Weeks 2, 24 (pooled studies) and 52 (SINUS-52). Subgroups with prior sinonasal surgery and coexisting asthma were analysed. At baseline in the pooled intention-to-treat population ( Significantly, more patients achieved improvement from moderate-to-severe symptoms to no-to-mild symptoms with dupilumab than placebo, regardless of prior surgery or coexisting asthma. Improvement was observed as early as Week 2 and continued through to Week 52.

Informations de copyright

© 2023 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.

Déclaration de conflit d'intérêts

PG receives clinical trial funding and is an advisory board member for 3NT, Argenx, Genentech, Novartis, Regeneron Pharmaceuticals Inc., Roche, Sanofi and Stallergenes Greer. SEL receives clinical trial funding and is an advisory board member for GlaxoSmithKline and Sanofi, receives clinical trial funding from AstraZeneca and Genentech, and is an advisory board member for Novartis and Regeneron Pharmaceuticals Inc. RAS receives research grants, fees for lectures and is an advisory board member for AstraZeneca, GlaxoSmithKline and Regeneron Pharmaceuticals Inc., receives fees for lectures and is an advisory board member for Grifols, Pharming and Sanofi, receives research grants and fees for lectures from Genentech, receives fees for lectures from Boehringer Ingelheim, OptiNose and Takeda, is an advisory board member for Aimmune Therapeutics, ALK, BioCryst, DBV Technologies and Pfizer, and receives research grants from Chiesi, Merck, Novartis and Stallergenes Greer. MW is a member of national and international scientific advisory boards (consulting), receives fees for lectures and research grants from ALK‐Abelló, Allakos, AstraZeneca, GlaxoSmithKline, HAL, Meda Pharmaceuticals, Novartis, Otonomy, Roche, Sanofi‐Aventis, Stallergenes Greer, Strekin and Teva. C‐CC, JAJ‐N, AHK and JM are employees and may hold stock and/or stock options in Sanofi. SK and SN are employees and shareholders of Regeneron Pharmaceuticals Inc. SS is a former employee and may hold stock and/or stock options in Regeneron Pharmaceuticals Inc.